RPL3L

Across TCGA pan-cancer cohorts, RPL3L Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPL3L data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RPL3L Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL3L expression acts as an unfavorable survival marker.

HNSC, LUSC, and PRAD are the cancer types where RPL3L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.122	0.685	.001	33	view →
LUSC	OS	Median	II,III,IV	0.500	0.743	<.001	28	view →
PRAD	DFS	Median	All	0.125	0.774	.021	6	view →
BLCA	DFS	Median	III,IV	0.198	0.550	.012	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPL3L–HNSC (DFS)

Open the HNSC breakdown →